Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jun;17(3):240-6.
doi: 10.1097/MED.0b013e3283391fd1.

Metabolic sequelae associated with androgen deprivation therapy for prostate cancer

Jason E Faris  1 , Matthew R Smith
Affiliations
Review

Metabolic sequelae associated with androgen deprivation therapy for prostate cancer

Jason E Faris et al. Curr Opin Endocrinol Diabetes Obes. 2010 Jun.

Abstract

Purpose of review: To summarize the metabolic alterations associated with androgen deprivation therapy (ADT) for prostate cancer and to evaluate the evidence linking ADT with an increased risk of diabetes and cardiovascular disease.

Recent findings: ADT by either bilateral orchiectomy or treatment with gonadotropin-releasing hormone agonists causes changes in body composition, alterations in lipid profiles, and decreased insulin sensitivity. The spectrum of metabolic changes during ADT is distinct from classically described metabolic syndrome. Population-based, linked cancer registry studies have consistently reported significant associations between ADT and greater risk for diabetes mellitus. Some but not all studies have reported a link between ADT and cardiovascular disease risk. Most studies have reported no increase in cardiovascular mortality following ADT.

Summary: ADT appears causally associated with diabetes mellitus. ADT is also linked to cardiovascular morbidity, although there is less evidence that this relationship is causal.

PubMed Disclaimer

Conflict of interest statement

The authors (Faris and Smith) declare no conflict of interest related to the contents of this manuscript.

Figures

Figure 1
Figure 1
Increased Incidence of Diabetes Mellitus and Myocardial Infarction with Androgen Deprivation Therapy [21]
See this image and copyright information in PMC

References

    1. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004 Jun 1;22(11):2141–9. - PMC - PubMed
    1. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005 Apr 15;103(8):1615–24. - PubMed
    1. Barry MJ, Delorenzo MA, Walker-Corkery ES, Lucas FL, Wennberg DC. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU international. 2006 Nov;98(5):973–8. - PMC - PubMed
    1. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. The New England journal of medicine. 1984 Nov 15;311(20):1281–6. - PubMed
    1. Garnick MB. Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer. Results of a prospectively randomized trial. Urology. 1986 Jan;27(1 Suppl):21–8. - PubMed

Publication types